Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL21382169 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL28392735 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL27683459 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL5889661 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL3089172 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL23091356 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL1675456 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL4612424 | 1.00 | SLC7A5 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL6534720 | 0.97 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL7110075 | 0.97 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384117-B2 | Connective tissue stimulating peptides | OCTANE ORTHOBIOLOGICS INC. (CA) | 2022-07-12 | — | — | US | disclosed |
| US-20190077831-A1 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2019-03-14 | — | — | US | disclosed |
| US-10202419-B2 | Connective tissue stimulating peptides | OCTANE ORTHOBIOLOGICS INC. (CA) | 2019-02-12 | — | — | US | disclosed |
| US-20160237117-A1 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2016-08-18 | — | — | US | disclosed |
| US-9133236-B2 | Connective tissue stimulating peptides | MILLENIUM BIOLOGIX INC. (CA) | 2015-09-15 | — | — | US | disclosed |
| US-20120156276-A1 | Connective tissue stimulating peptides | MILLENIUM BIOLOGIX INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20100021940-A1 | Method for Determining the Activity of a Protease in a Sample | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| US-7491691-B2 | Connective tissue stimulating peptides | OCTANE ORTHOBIOLOGICS INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| EP-2010669-A1 | METHOD FOR DETERMINING THE ACTIVITY OF A PROTEASE IN A SAMPLE | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007117199-A1 | METHOD FOR DETERMINING THE ACTIVITY OF A PROTEASE IN A SAMPLE. | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | WO | disclosed |
| US-20050288229-A1 | Connective Tissue Stimulating Peptides | MILLENIUM BIOLOGIX INC. (CA) | 2005-12-29 | — | — | US | disclosed |
| EP-1504033-A2 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2005-02-09 | — | — | EP | disclosed |
| WO-2004041828-A1 | METHOD OF USING A PORPHYRIN-LIKE MOLECULE CONJUGATED WITH AN ANTI-CANCER DRUG FOR THE TREATMENT OF CANCER | HAN IN SUK (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003093314-A2 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021940-A1 | Method for Determining the Activity of a Protease in a Sample | CTRL, PRSS1, PREP | SLC7A5 4284/4885SLC1A3 3901/4885SLC1A2 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.